Bright Minds Biosciences Inc. (DRUG) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 50.3 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, DRUG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($59.18) or 200D SMA ($73.27) invalidates the momentum regime and cuts Target Base ($57.46) toward Bear Floor ($44.82).
Bright Minds Biosciences Inc. (DRUG) surged +2.48% to $56.69, trading at 12% of its 52-week range ($47.23 – $123.75). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
US GDP growth running at a 3.4% annual pace puts risk assets back in focus, and that includes Canadian biotech stocks that can react sharply when money flows into higher risk ideas. Stronger US activity can support healt
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
Oil prices recently moved above $110 a barrel as conflict risks around Iran and Saudi Arabia increased, and that puts global inflation and healthcare costs back in the spotlight. For Canadian biotech stocks, that renewed
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DRUG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DRUG. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Bright Minds Biosciences Inc. (DRUG) ranks #189 by composite RQD confidence (61/100, grade C-) and #430 by equity capitalization ($556.7M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with DRUG at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DRUG
ACTIVE
Bright Minds Biosciences Inc. | C- | 61/100 | — | — | — | +2.48% | $556.7M | Benchmark Subject |
| EVO Evotec SE | D+ | 57/100 | — | — | — | -1.56% | $562.1M | /evo-vs-drug → |
| PBYI Puma Biotechnology Inc | C+ | 67/100 | 17.5x | 74.5% | 29.3% | -0.75% | $544.1M | /pbyi-vs-drug → |
| STTK Shattuck Labs Inc. | E | 31/100 | — | — | -35.0% | -1.46% | $574.1M | /sttk-vs-drug → |
| NGNE Neurogene Inc. | D- | 36/100 | — | — | -35.0% | -5.26% | $576.7M | /ngne-vs-drug → |
Bright Minds Biosciences Inc. (DRUG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $556.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Bright Minds Biosciences Inc. (NASDAQ: DRUG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $56.69 (+2.48% 1D, market cap $556.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DRUG ranks #189 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRUG carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVO (Evotec SE) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $562.1M) and PBYI (Puma Biotechnology Inc) posts a C+ grade (67/100 RQD, P/E 17.5x, ROIC 29.3%, cap $544.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
For Bright Minds Biosciences Inc. (DRUG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #189 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
DRUG last traded at $56.69 (+2.48% on volume of 67,555 shares), positioning the stock -4.21% below its 50-day simple moving average ($59.18) and -22.63% below its 200-day simple moving average ($73.27). Across its 52-week range of $47.23 to $123.75, DRUG sits at the 12.4% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($49.60 to $63.78).
Why DRUG Stock surged +2.48% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.